Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.65 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30297506 | 0.85 | TSHR (0.55) | AKR1B1AKR1B10MAPTAKR1A1TSHR | |
| SCHEMBL11278275 | 0.82 | AKR1B10 (0.66) | AKR1B1AKR1B10MAPTAKR1A1 | |
| SCHEMBL7867894 | 0.79 | AKR1B10 (0.80) | AKR1B1AKR1B10MAPTAKR1A1 | |
| Sorbinil SCHEMBL48877 | 0.79 | AKR1B10 (1.00) | AKR1B1AKR1B10MAPTAKR1A1 | |
| SCHEMBL11342164 | 0.79 | AKR1B1 (0.71) | AKR1B1AKR1B10MAPTAKR1A1 | |
| SCHEMBL24697564 | 0.79 | AKR1B1 (0.59) | AKR1B1AKR1B10MAPTAKR1A1 | |
| SCHEMBL1982939 | 0.79 | AKR1B10 (0.71) | AKR1B1AKR1B10MAPTAKR1A1 | |
| SCHEMBL10921763 | 0.79 | AKR1B1 (0.71) | AKR1B1AKR1B10MAPTAKR1A1 | |
| SCHEMBL11349834 | 0.79 | AKR1B10 (0.59) | AKR1B1AKR1B10MAPTAKR1A1 | |
| Sorbinil SCHEMBL29599732 | 0.79 | AKR1B10 (1.00) | AKR1B1AKR1B10MAPTAKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| EP-3288939-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | AbbVie Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| EP-0111387-A1 | Regeneration of 6-fluoro-4-chromanone from by-products in the synthesis of sorbinil | PFIZER INC. (US) | 1984-06-20 | — | — | EP | disclosed |
| US-4431828-A | Regeneration of 6-fluoro-4-chromanone from by-products in the synthesis of sorbinil | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| WO-1983003542-A1 | HYDANTOIN THERAPEUTIC AGENTS | ALCON LAB INC (US) | 1983-10-27 | — | — | WO | disclosed |
| EP-0092386-A2 | Hydantoin therapeutic agents | ALCON LABORATORIES, INC. (US) | 1983-10-26 | — | — | EP | disclosed |
| US-4282229-A | FOR DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
| US-4258054-A | ANTIDIABETIC | PFIZER INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4210756-A | Tetrahydroquinoline hydantoins for chronic diabetic complications | PFIZER INC. (US) | 1980-07-01 | — | — | US | disclosed |
| US-4209630-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1980-06-24 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266532-B2 | Tricyclic modulators of TNF signaling | TNF, TNFRSF1A, CD40 | AKR1B1 583/4885AKR1B10 775/4885MAPT 3059/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | AKR1B1 69/4885AKR1B10 165/4885MAPT 715/4885 |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | AKR1B1 84/4885AKR1B10 236/4885MAPT 650/4885 |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | AKR1B1 583/4885AKR1B10 775/4885MAPT 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.